Fawson Pharmaceutical: interim report 2022
Trade Alert: The CEO & Executive Director Of Fusen Pharmaceutical Company Limited (HKG:1652), Zhiming Cao, Has Just Spent CN¥1.9m Buying 1.5% More Shares
Investors who take an interest in Fusen Pharmaceutical Company Limited (HKG:1652) should definitely note that the CEO & Executive Director, Zhiming Cao, recently paid HK$0.96 per share to buy HK$1
Fawson Pharmaceutical: interim results announcement for the six months ended June 30, 2022
Fusen Pharmaceutical Forecasts Swing to Loss in January-June Results
02:34 AM EDT, 08/22/2022 (MT Newswires) -- Fusen Pharmaceutical (HKG:1652) expects to report a loss attributable to owners of 5 million yuan ($732,407) to 9 million yuan for the six months ended June
Fusen Pharmaceutical: profit warning
Fusen Pharmaceutical: annual report 2021
Fusen Pharmaceutical Cuts Final Dividend as Profit, Revenue Slump in FY21
11:15 PM EDT, 03/23/2022 (MT Newswires) -- Fusen Pharmaceutical (HKG:1652) slashed its final dividend for 2021 as both profit and revenue fell, according to a Thursday disclosure. Attributable net pr
Fawson Pharmaceutical: annual results announcement for the year ended December 31, 2021
Fusen Pharmaceutical: notice of Board meeting
Fusen Pharmaceutical (01652.HK) buys back 289000 shares with an investment of 354000 yuan.
[Caihua News] Fusen Pharmaceutical (01652.HK) announced that it will repurchase 289000 shares on January 17, 2022 at a price ranging from HK $1.21 to HK $1.23 per share, involving an investment of 354000 yuan. The cumulative number of securities repurchased so far this year (since the passing of the ordinary resolution) is 8.541 million shares, accounting for 1.1 per cent of the number of shares issued at the time of the passing of the ordinary resolution.